Mazdutide vs Tirzepatide
Mazdutide (Dual GLP-1/glucagon receptor agonist) and Tirzepatide (Dual GIP/GLP-1 receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Mazdutide | Tirzepatide |
|---|---|---|
| Compound class | Dual GLP-1/glucagon receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | Not documented | 39 amino acids |
| Molecular weight | Not documented | 4813.5 g/mol |
| Half-life | Not documented | ~5 days |
| Origin | An investigational dual agonist targeting the GLP-1 and glucagon receptors, developed by Eli Lilly and licensed to Innovent Biologics for the Chinese market (also known as IBI362 or LY3305677). It has been evaluated in clinical trials in the 2020s. | Developed by Eli Lilly as the first approved dual agonist targeting both the GIP and GLP-1 receptors. It received first FDA approval in 2022. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Mazdutide works
Mazdutide is a synthetic peptide agonist that activates both the GLP-1 and glucagon receptors, structurally based on the glucagon/oxyntomodulin family. GLP-1 agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, while glucagon-receptor agonism is proposed to increase energy expenditure and influence hepatic lipid metabolism. The combined activity is being studied for effects on body weight and metabolic parameters.
How Tirzepatide works
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Combined agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake. It carries a C20 fatty-diacid moiety enabling albumin binding and a prolonged half-life supporting once-weekly administration.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Described in identical terms for both
Mazdutide
Tirzepatide
What sets each apart
Mazdutide
Mazdutide differs from tirzepatide by pairing GLP-1 with glucagon-receptor agonism (rather than GIP), and from single GLP-1 agonists by its dual-receptor action.
Tirzepatide
Tirzepatide differs from semaglutide and other single GLP-1 agonists by simultaneously engaging the GIP receptor, a mechanism proposed to contribute to its metabolic effects.
Frequently asked questions
How does mazdutide differ from tirzepatide?
Both are dual agonists, but mazdutide pairs GLP-1 with glucagon-receptor activity, whereas tirzepatide pairs GLP-1 with GIP-receptor activity. The glucagon arm is the mechanistic feature researchers study for its effects on energy expenditure and hepatic fat. Mazdutide is earlier in development and less broadly characterized.
What does mazdutide's dosing schedule imply for study design?
Mazdutide is administered once weekly with a multi-week escalation, consistent with a half-life-extended acylated peptide suited to weekly dosing. Protocols therefore include several weeks of titration before maintenance-phase readouts. Precise half-life figures are less consistently reported in the literature than for semaglutide or tirzepatide.
What is mazdutide and what receptors does it target?
Mazdutide (IBI362 / LY3305677) is a once-weekly dual agonist based on a mammalian oxyntomodulin analogue that activates both the GLP-1 and glucagon receptors. The glucagon-receptor arm — associated in research with increased energy expenditure and hepatic fat effects — distinguishes it from GLP-1 mono-agonists. It is studied in obesity and metabolic models, with much of the clinical work conducted in Chinese populations.
What is tirzepatide and how is its mechanism different from a GLP-1 mono-agonist?
Tirzepatide is a dual agonist that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors from a single synthetic peptide backbone with a C20 fatty-diacid for half-life extension. The added GIP activity is the key distinction from GLP-1-only agonists like semaglutide. It is studied in models of glucose handling, appetite, and body-weight change.
What is tirzepatide's half-life and what does it imply for study design?
Tirzepatide has a reported half-life of about 5 days (~117 hours), supporting once-weekly administration in the literature. Steady state is generally reached after about 4 weeks at a given dose, so protocols include a multi-week escalation before maintenance-phase readouts. The multi-day half-life also means a washout of several weeks after discontinuation.
How is tirzepatide dose-escalated in research protocols?
Published protocols escalate weekly from 2.5 mg upward through 5, 7.5, 10, 12.5 and up to 15 mg once weekly, with each step commonly held about 4 weeks. As with other incretin agonists, escalation is used to limit gastrointestinal tolerability issues. These are reference figures for research context only, not human dosing guidance.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.